| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 8 | -224,267 | 100% | $188.92 | -$42,369,216 |
| Net | -8 | -224,267 | -100% | -$42,369,216 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Stephen H. Rusckowski | Director | $47,867,056 | 06 Mar 2023 | ||
| J. E. Davis | CEO and President, Director | $27,238,398 | -$19,317,034 | -41% | 04 Mar 2026 |
| Catherine T. Doherty | EVP, Regional Businesses | $14,702,234 | -$6,964,737 | -32% | 04 Mar 2026 |
| Mark Guinan | Executive Vice President & CFO | $13,108,142 | 07 Mar 2022 | ||
| Michael E. Prevoznik | SVP & General Counsel | $8,841,829 | -$6,505,262 | -42% | 04 Mar 2026 |
| Timothy M. Ring | Director | $7,948,934 | 01 Oct 2025 | ||
| Sam Samad | Executive Vice President & CFO | $7,870,127 | 04 Mar 2026 | ||
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | $7,592,213 | 07 Mar 2022 | ||
| Michael J. Deppe | SVP, Corp. Controller & CAO | $6,881,798 | 04 Mar 2026 | ||
| Gary M. Pfeiffer | Director | $5,368,214 | -$270,317 | -4.8% | 22 Oct 2025 |
| Timothy L. Main | Director | $4,646,153 | 15 May 2025 | ||
| Gail R. Wilensky | Director | $4,162,722 | 17 May 2023 | ||
| Mark E. Delaney | SVP & Chief Commercial Officer | $3,341,671 | -$1,795,483 | -35% | 04 Mar 2026 |
| Karthik Kuppusamy | SVP, Clinical Solutions | $3,139,082 | -$2,732,653 | -47% | 04 Mar 2026 |
| Vicky B. Gregg | Director | $3,138,806 | -$239,700 | -7.1% | 28 Jan 2026 |
| Patrick Plewman | SVP for Diagnostic Services | $3,133,979 | -$4,544,030 | -59% | 04 Mar 2026 |
| Denise M. Morrison | Director | $1,897,896 | 15 May 2025 | ||
| Wright Lassiter III | Director | $1,722,051 | 28 Jan 2026 | ||
| Mark A. Gardner | SVP of Molecular Gen & Oncol | $1,539,829 | 24 Sep 2024 | ||
| Tracey Doi | Director | $1,146,653 | 15 May 2025 | ||
| Helen Torley | Director | $769,122 | 25 May 2021 | ||
| Luis Diaz | Director | $716,260 | 15 May 2025 | ||
| Robert B. Carter | Director | $496,211 | 28 Jan 2026 | ||
| Timothy C. Wentworth | Director | $41,118 | 09 Mar 2026 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Timothy C. Wentworth | DGX | Common Stock | Award | 215 | 215 | 09 Mar 2026 | Direct | |||
| Catherine T. Doherty | DGX | Common Stock | Sale | -7.65% | $1,146,115 | $206.21 | -5,558 | 67,122 | 05 Mar 2026 | Direct |
| Michael E. Prevoznik | DGX | Common Stock | Sale | -9.36% | $799,682 | $206.21 | -3,878 | 37,557 | 05 Mar 2026 | Direct |
| Patrick Plewman | DGX | Common Stock | Sale | -15.8% | $588,730 | $206.21 | -2,855 | 15,198 | 05 Mar 2026 | Direct |
| Sam Samad | DGX | Common Stock | Tax liability | -18.8% | -7,720 | 33,268 | 04 Mar 2026 | Direct | ||
| Sam Samad | DGX | Common Stock | Award | 51.6% | 13,947 | 40,988 | 04 Mar 2026 | Direct | ||
| Catherine T. Doherty | DGX | Common Stock | Tax liability | -7.4% | -5,806 | 72,680 | 04 Mar 2026 | Direct | ||
| Catherine T. Doherty | DGX | Common Stock | Award | 16.9% | 11,364 | 78,486 | 04 Mar 2026 | Direct | ||
| Mark E. Delaney | DGX | Common Stock | Tax liability | -16.4% | -2,326 | 11,864 | 04 Mar 2026 | Direct | ||
| Mark E. Delaney | DGX | Common Stock | Award | 66.8% | 5,682 | 14,190 | 04 Mar 2026 | Direct | ||
| Michael E. Prevoznik | DGX | Common Stock | Tax liability | -7.49% | -3,354 | 41,435 | 04 Mar 2026 | Direct | ||
| Michael E. Prevoznik | DGX | Common Stock | Award | 19.3% | 7,232 | 44,789 | 04 Mar 2026 | Direct | ||
| J. E. Davis | DGX | Common Stock | Tax liability | -15.6% | -26,414 | 142,423 | 04 Mar 2026 | Direct | ||
| J. E. Davis | DGX | Common Stock | Award | 44.1% | 51,652 | 168,837 | 04 Mar 2026 | Direct | ||
| Patrick Plewman | DGX | Common Stock | Tax liability | -13.5% | -2,827 | 18,053 | 04 Mar 2026 | Direct | ||
| Patrick Plewman | DGX | Common Stock | Award | 37.4% | 5,682 | 20,880 | 04 Mar 2026 | Direct | ||
| Michael J. Deppe | DGX | Common Stock | Tax liability | -2.09% | -750 | 35,196 | 04 Mar 2026 | Direct | ||
| Michael J. Deppe | DGX | Common Stock | Award | 4.27% | 1,473 | 35,946 | 04 Mar 2026 | Direct | ||
| Karthik Kuppusamy | DGX | Common Stock | Sale | -16.4% | $538,372 | $204.86 | -2,628 | 13,441 | 04 Mar 2026 | Direct |
| Karthik Kuppusamy | DGX | Common Stock | Award | 62.8% | 6,200 | 16,069 | 04 Mar 2026 | Direct | ||
| Catherine T. Doherty | DGX | Common Stock | Sale | -0.93% | $131,285 | $207.73 | -632 | 67,122 | 03 Mar 2026 | Direct |
| Michael E. Prevoznik | DGX | Common Stock | Sale | -1.38% | $109,266 | $207.73 | -526 | 37,557 | 03 Mar 2026 | Direct |
| Patrick Plewman | DGX | Common Stock | Sale | -2.63% | $85,169 | $207.73 | -410 | 15,198 | 03 Mar 2026 | Direct |
| Catherine T. Doherty | DGX | Common Stock | Tax liability | -0.95% | -648 | 67,754 | 02 Mar 2026 | Direct | ||
| Sam Samad | DGX | Common Stock | Tax liability | -3.11% | -869 | 27,041 | 02 Mar 2026 | Direct | ||
| Michael E. Prevoznik | DGX | Common Stock | Tax liability | -0.75% | -288 | 38,083 | 02 Mar 2026 | Direct | ||
| J. E. Davis | DGX | Common Stock | Sale | -7.86% | $2,125,200 | $212.52 | -10,000 | 117,185 | 02 Mar 2026 | Direct |
| J. E. Davis | DGX | Common Stock | Tax liability | -2.28% | -2,968 | 127,185 | 02 Mar 2026 | Direct | ||
| Patrick Plewman | DGX | Common Stock | Tax liability | -1.45% | -230 | 15,608 | 02 Mar 2026 | Direct | ||
| Karthik Kuppusamy | DGX | Common Stock | Tax liability | -2.03% | -205 | 9,869 | 02 Mar 2026 | Direct | ||
| Mark E. Delaney | DGX | Common Stock | Tax liability | -2.16% | -188 | 8,508 | 02 Mar 2026 | Direct | ||
| Michael J. Deppe | DGX | Common Stock | Tax liability | -0.25% | -88 | 34,473 | 02 Mar 2026 | Direct | ||
| Patrick Plewman | DGX | Common Stock | Sale | -5.7% | $196,227 | $204.83 | -958 | 15,838 | 19 Feb 2026 | Direct |
| Michael E. Prevoznik | DGX | Common Stock | Sale | -2.81% | $227,566 | $204.83 | -1,111 | 38,371 | 19 Feb 2026 | Direct |
| Catherine T. Doherty | DGX | Common Stock | Sale | -2.05% | $293,521 | $204.83 | -1,433 | 68,402 | 19 Feb 2026 | Direct |
| Patrick Plewman | DGX | Common Stock | Tax liability | -3.1% | -537 | 16,796 | 18 Feb 2026 | Direct | ||
| Patrick Plewman | DGX | Common Stock | Award | 12.7% | 1,952 | 17,333 | 18 Feb 2026 | Direct | ||
| Patrick Plewman | DGX | Non-Qualifed Stock Option (right to buy) | Award | 9,009 | 9,009 | 18 Feb 2026 | Direct | |||
| Sam Samad | DGX | Common Stock | Tax liability | -6.28% | -1,865 | 27,841 | 18 Feb 2026 | Direct | ||
| Sam Samad | DGX | Common Stock | Award | 15.4% | 3,965 | 29,706 | 18 Feb 2026 | Direct | ||
| Sam Samad | DGX | Non-Qualifed Stock Option (right to buy) | Award | 18,303 | 18,303 | 18 Feb 2026 | Direct | |||
| Michael E. Prevoznik | DGX | Common Stock | Tax liability | -1.61% | -648 | 39,482 | 18 Feb 2026 | Direct | ||
| Michael E. Prevoznik | DGX | Common Stock | Award | 5.28% | 2,013 | 40,130 | 18 Feb 2026 | Direct | ||
| Michael E. Prevoznik | DGX | Non-Qualifed Stock Option (right to buy) | Award | 9,289 | 9,289 | 18 Feb 2026 | Direct | |||
| J. E. Davis | DGX | Common Stock | Tax liability | -4.54% | -6,184 | 130,153 | 18 Feb 2026 | Direct | ||
| J. E. Davis | DGX | Common Stock | Award | 13.2% | 15,857 | 136,337 | 18 Feb 2026 | Direct | ||
| J. E. Davis | DGX | Non-Qualifed Stock Option (right to buy) | Award | 73,225 | 73,225 | 18 Feb 2026 | Direct | |||
| Catherine T. Doherty | DGX | Common Stock | Tax liability | -1.64% | -1,161 | 69,835 | 18 Feb 2026 | Direct | ||
| Catherine T. Doherty | DGX | Common Stock | Award | 4.3% | 2,928 | 70,996 | 18 Feb 2026 | Direct | ||
| Catherine T. Doherty | DGX | Non-Qualifed Stock Option (right to buy) | Award | 13,514 | 13,514 | 18 Feb 2026 | Direct |